Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Confounding in Epidemiological Studies01:27

Confounding in Epidemiological Studies

Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This phenomenon...
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Biostatistics: Overview01:20

Biostatistics: Overview

Biostatistics plays a crucial role in understanding and analyzing data in healthcare and biology. Biostatisticians conduct experiments, gather evidence, and draw meaningful conclusions using statistical methods and techniques. Different variables form the foundation of biostatistical analysis, allowing researchers to understand and interpret data effectively. These variables are classified into different types, each serving a specific purpose in statistical analysis.
Discrete variables are...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.

PloS one·2025
Same author

Medication utilization patterns among patients with rheumatoid arthritis and coexisting autoimmune conditions.

Journal of managed care & specialty pharmacy·2025
Same author

Risk of Hypertension and Chronic Kidney Disease Following Aldosterone Dysregulation.

American journal of hypertension·2025
Same author

Predictive Modeling of Heterogeneous Treatment Effects in RCTs: A Scoping Review.

JAMA network open·2025
Same author

Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age.

Vaccine·2025
Same author

Early-Onset Colorectal Cancer Survival by Race and Ethnicity in a Large Community-Based Insured Population.

Gastro hep advances·2025

Related Experiment Video

Updated: May 9, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Multivariable confounding adjustment in distributed data networks without sharing of patient-level data.

Sengwee Toh1, Marsha E Reichman, Monika Houstoun

  • 1Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.

Pharmacoepidemiology and Drug Safety
|July 24, 2013
PubMed
Summary

Two methods for analyzing multi-site health data without sharing patient-level information produced similar results in a study of drug safety. These approaches, case-centered analysis and meta-analysis, are valuable for public health surveillance and comparative effectiveness research.

Keywords:
Mini-Sentinelactive surveillanceconfoundingdisease risk scoresdistributed data networkpharmacoepidemiologypropensity scores

More Related Videos

Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 24, 2010

Related Experiment Videos

Last Updated: May 9, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 24, 2010

Area of Science:

  • Health Informatics
  • Pharmacoepidemiology
  • Biostatistics

Background:

  • Analyzing multi-site data is crucial for public health surveillance and comparative effectiveness research.
  • Sharing granular patient-level data is often hindered by security, privacy, and legal concerns.

Purpose of the Study:

  • To describe and compare two methods for adjusting confounding in multi-site studies without requiring patient-level data sharing.
  • To evaluate the risks of angioedema associated with specific medications using these novel approaches.

Main Methods:

  • A propensity score-stratified case-centered logistic regression analysis using aggregated risk set data.
  • An inverse variance-weighted meta-analysis requiring only site-specific hazard ratios and variances.
  • Simulations were conducted to further compare the two analytical methods.

Main Results:

  • Both methods yielded similar adjusted hazard ratios for angioedema risk associated with ACEIs, ARBs, and aliskiren compared to beta-blockers.
  • Case-centered analysis: HR ACEIs=3.04, ARBs=1.16, Aliskiren=2.85.
  • Meta-analysis: HR ACEIs=2.98, ARBs=1.15, Aliskiren=2.86. Simulations indicated potential differences under specific scenarios.

Conclusions:

  • Case-centered analysis and meta-analysis provide comparable results for multi-site studies without sharing patient-level data.
  • These methods are viable alternatives for health data analysis when data sharing is restricted.
  • Potential discrepancies between methods may arise in different study settings, warranting careful consideration.